Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States
Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States
复制标题
DOI：
10.1080/25787489.2024.2312318
复制
发表时间：
2024-01-29
影响因子：
1.6
通讯作者：
Sauceda，John A.
中科院分区：
文献类型：
--
作者：
Dube，Karine;Ndukwe，Samuel O.;Sauceda，John A.
BackgroundThere是有限的系统信息的观点参加了密集的组合艾滋病毒治疗相关的试验包括一个扩展的分析治疗中断（ATI）。ObjectiveAssessment和了解经验的人与艾滋病毒参与了一个组合艾滋病毒治疗相关的试验与扩展ATI.MethodsThe试验包括五个干预措施，其次是ATI持续长达52周。从2022年至2023年，我们在研究参与者的扩展ATI后对其进行了深入访谈。访谈录音，转录，和analyzedviconventional的主题analysis.ResultsWe采访了7名参与者。大多数是男性、白色和非西班牙裔，中位年龄为37岁。对研究团队的信任、科学的利他主义和成为干预后控制者的希望是参加试验的关键动机。受访者报告称，他们对参与试验和延长ATI的决定感到满意。大多数人讲述了与ATI期间病毒反弹有关的担忧情绪。参与者报告了ART重新启动后的失败和缓解。四个面临的挑战，保护合作伙伴免受艾滋病毒在他们的ATI，如试图找出他们的合作伙伴（S）使用暴露前prophylaxis.ConclusionsOur研究结果表明，潜在的改善未来ATI试验参与者的经验，如更强大的资源，心理社会支持和合作伙伴的保护。投入更大的努力来了解参与者ATI的经验，可以告知未来以参与者为中心的HIV治愈试验方案的设计。
BackgroundThere is limited systematic information available about the perspectives of participants enrolled in intensive combination HIV cure-related trials inclusive of an extended analytical treatment interruption (ATI).ObjectiveTo assess and understand experiences of people with HIV involved in a combination HIV cure-related trial with an extended ATI.MethodsThe trial included five interventions and was followed by an ATI lasting up to 52 wk. From 2022 – 2023, we conducted in-depth interviews with study participants following their extended ATIs. Interviews were audio-recorded, transcribed, and analyzedviaconventional thematic analysis.ResultsWe interviewed seven participants. The majority were male, White, and non-Hispanic, with a median age of 37 years. Trust in the research team, scientific altruism and hope of becoming a post-intervention controller were key motivators for joining the trial. Interviewees reported being satisfied with their decision to participate in the trial and the extended ATI. Most recounted feelings of worry related to viral rebound during the ATI. Participants reported both defeat and relief with ART restart. Four faced challenges with protecting partners from HIV during their ATI, such as trying to find out if their partner(s) were using pre-exposure prophylaxis.ConclusionsOur findings demonstrate potential improvements for future ATI trial participant experiences, such as more robust resources for psychosocial support and partner protections. Dedicating greater effort to understanding participant ATI experiences can inform the design of future participant-centered HIV cure trial protocols.